Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOLYNC: Neoadjuvant Nivolumab in Cervical Cancer
NCT07653503Phase 1Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in Cervical Cancer (CC), sponsored by University Medical Center Groningen. Primary endpoints: Proportion of participants undergoing planned standard surgical treatment without treatment-related delay or cancellation at 2 months and Pathologic response rate. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07653503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07653503.